Skip Ribbon Commands
Skip to main content

The First Cases Of Preserflo Microshunt in the Kingdom

11/9/2022

King Abdulaziz Medical City – Jeddah Performs The First Cases Of

Preserflo Microshunt in the Kingdom

King Abdulaziz Medical City – Jeddah, has accomplished major achievements in which it has made a complete, yet a comprehensive health system that aligns and simulates the international requirements for quality in health services field. The Department of Opthamology have performed the first two cases of Minimally Invasive Glaucoma Surgery using Presserflo Microshunt implant, making KAMC-JD the first center in the kingdom to perform such procedure.

Dr. Alaa Mofti, Assisstant Professor of Ophthalmology at King Saud Bin Abdulaziz University for Health Sciences - Jeddah, Glaucoma and Advanced Anterior Segment Consultant stated that on October 31, 2022, two cases were operated using the preserflo microshunt which went successful. The first case was for 27 year old male who had juvenile glaucoma and was unable to stop using his anti-glaucoma medications due to his condition but suffers from treatment intolerance and allergies, while the second case was for a 64 year old lady who suffered from cataracts and Advance stage glaucoma with uncontrolled eye pressure on maximum medical therapy. Both patients were diagnosed at the ophthalmology clinic after series of interocular pressure, measurements, optic nerve analysis and visual field testing. Surgical options have been discussed with both patients. Due to the advance level of their disease, conventional glaucoma surgery techniques could result in relatively higher postoperative complication rates, so a recommendation was made to use the microshunt as a safer alternative.

The Preserflo Microshunt have been recently approved by the Saudi FDA, and is considered one of the advances in minimally invasive glaucoma surgery. The device offered higher safety profile due to its small size, measuring at 8.5 mm in length and width a 70 micron lumen. The device is also made off a proprietary material called poly(styrene-block-isobutylene-block-styrene) which is non-degradable and has better bio compatibility with human tissue, therefore, reducing the rate of postoperative scarring on fibrosis. The implant is considered a minimally invasive option that can be offered to patients in efforts to avoid more invasive traditional glaucoma surgeries.

Both procedures were performed by Dr.Alaa Mofti with the assistance of Dr. Haifaa Kayal, Consultant Anesthesia. The male patient underwent Preserflo implant with the use of antimetabolites, whereas the female patient underwent combined cataract surgery and Preserflo with antimetabolite. Dr. Mofti mentioned that both patients did well postoperatively, with stable intra ocular pressure off all glaucoma medications.

It is worth mentioning that the department of ophthalmology at KAMC-JD includes highly trained experts with international qualifications and is equipped with the latest medical and surgical technologies in Ophthalmology. The department performs cataract surgeries, corneal transplants, complex anterior segment surgeries, minimal invasive glaucoma surgeries, retinal surgeries and pediatric ophthalmology surgeries. Also, in 2021 the department performed the first cases of (iStents inject W) and (XEN gel implant) as the first medical center in the western region.

Last Modified

11/27/2022 2:10 PM